Wells Fargo raises ABBV target to $295 from $260Wells Fargo 上调目标价 艾伯维 (ABBV)：$260 → $295
Rating Or Target Action
Wells Fargo raised its price target for AbbVie (ABBV) by 13.5% to $295 on July 10, 2026, up from its prior target of $260. This adjustment is a standalone price target revision, with no change to the firm’s explicit stock rating. The large-cap biopharmaceutical firm has a current market capitalization of approximately $461.3 billion, and closed at $248.08 on July 10, 2026, making the new target price above the current share price.
Consensus Read-Through
This revision reflects a more bullish near-term valuation outlook for AbbVie from Wells Fargo. As of June 1, 2026, the broader analyst consensus for ABBV split 8 Strong Buy, 16 Buy, and 8 Hold ratings, with no Sell or Strong Sell calls, so this price target adjustment aligns with the existing bullish baseline of Wall Street coverage.
Cross-Checks
Two concrete independent signals validate the context of this revision: First, AbbVie’s Q1 2026 earnings report, released April 29, 2026, beat consensus estimates, with adjusted EPS of $2.65 vs. the $2.59 forecast, and total revenue of $15.002 billion vs. the $14.717 billion consensus. Second, SEC Form 4 filings dated July 2, 2026, show two AbbVie directors—Edward J. Rapp and Susan E. Quaggin—received stock awards of 134 shares and 62 shares respectively, at a grant price of $251.64 per share, valued at $33,720 and $15,602.
Limits And Next Watch
This signal is solely Wells Fargo’s proprietary valuation update, and does not represent InvestLog’s official recommendation or price target. It does not incorporate the upcoming July 31, 2026, quarterly earnings report for AbbVie, nor does it account for sector-wide regulatory risks or unexpected macroeconomic shifts. Next watch: Monitor whether additional Wall Street firms issue comparable price target adjustments for ABBV, and how AbbVie’s Q2 2026 earnings results compare to consensus estimates on July 31.
评级/目标价动作
富国银行（Wells Fargo）于2026年7月10日将艾伯维（ABBV）的目标价从260美元上调至295美元，上调幅度达13.5%。此次调整仅涉及目标价修订，未改变该机构对艾伯维的明确评级。艾伯维当前市值约为4613亿美元，7月10日收盘价为248.08美元，新目标价高于当前股价。
市场预期变化
该调整反映富国银行对艾伯维短期估值前景的更乐观判断。截至2026年6月1日，市场对艾伯维的分析师评级分布为8个强力买入、16个买入、8个持有，无卖出或强力卖出评级，此次上调目标价与整体分析师的看涨基调一致。
交叉验证
本次调整可通过两项独立信号交叉验证：其一，艾伯维2026年4月29日发布的2026年第一季度财报超出市场预期，调整后每股收益为2.65美元，高于预期的2.59美元，总营收达150.02亿美元，高于预期的147.17亿美元。其二，2026年7月2日的SEC Form4文件显示，艾伯维两名董事Edward J Rapp和Susan E Quaggin分别获得134股和62股股票奖励，授予价为251.64美元/股，对应价值分别为33720美元和15602美元。
边界与下一步
本信号仅代表富国银行的专有估值调整，不构成InvestLog的任何投资建议或目标价。该调整未纳入艾伯维2026年7月31日即将发布的第二季度财报结果，也未涵盖医药行业监管风险或宏观经济波动等系统性因素。后续关注：留意是否有其他华尔街机构跟进调整艾伯维的目标价，以及7月31日发布的季度财报是否符合或超出市场预期。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。